Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2022 Publisher: Aventis Pharma Limited, 410 Thames Valley Park Drive, Reading, Berkshire, RG6 1PT, UK Trading as: Sanofi, 410 Thames Valley Park Drive, Reading, Berkshire, RG6 1PT, UK
Oruvail 100 mg Prolonged-Release Capsules, Hard.
| Pharmaceutical Form |
|---|
|
Controlled release capsules. |
Ketoprofen 100 mg.
| Active Ingredient | Description | |
|---|---|---|
| Ketoprofen |
Ketoprofen is a non-steroidal anti-inflammatory drug. It has anti-inflammatory and analgesic actions. |
| List of Excipients |
|---|
|
Pellets: Sugar spheres Capsule shell – body: Gelatin Capsule shell – cap: Gelatin |
Securitainer or HDPE bottle containing 100 capsules.
UPVC/Aluminium foil blister or UPVC coated with PVDC aluminium foil blister containing either 8, 28, 30 or 56 capsules.
Not all pack sizes may be marketed.
Aventis Pharma Limited, 410 Thames Valley Park Drive, Reading, Berkshire, RG6 1PT, UK
Trading as: Sanofi, 410 Thames Valley Park Drive, Reading, Berkshire, RG6 1PT, UK
PL 04425/0597
04 September 2006
| Drug | Countries | |
|---|---|---|
| ORUVAIL | Australia, Ireland, New Zealand, United Kingdom |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
